We are a biotechnology company specialized in the development, production and commercialization of solutions for animal and environmental health. We aim to collaborate in strengthening the sanitary status of each country, fostering new productive developments, and ensuring animal, human and environmental welfare. Our products are present in over 60 countries in America, Asia, Europe, the Middle East, North Africa and Oceania. We are a team of +1000 collaborators worldwide, with a modern management that integrates multiple nationalities. We are supported by our background and constant evolution. We are driven by an inquisitive spirit in the pursuit of anticipating and thinking innovative solutions for animal health issues, through different business models. We work with various international institutions to achieve innovative solutions that allow us to properly address the specific animal health needs of each context. We have a top-notch professional technical service that supports and assists producers and veterinarians to apply technologies correctly. By means of our knowledge and experience, we contribute to improve productivity rates and animal care. At Biogénesis Bagó we work aligned with the concept of “One Health”, which establishes that “human health and animal health are interdependent and linked to the ecosystem in which they coexist” We are committed to the prevention, control and elimination of zoonoses in different regions of the world. We are continuously working on prevention programs through the use of safe, effective, and quality vaccines, thus providing health to all species we focus on. Our vaccine against foot-and-mouth disease is recognized as a world-class product that meets the highest quality standards, validated by the most demanding health authorities. We are one of the main providers of anti-rabies, canine and feline, vaccines for organizations that attend public health campaigns.
BIOCLONAL
BioClonal is a Spanish biotech company enabling immune responses against disease targets that were previously considered out of reach. Founded in 2022 and based in Zaragoza, BioClonal has developed a proprietary platform that unlocks the generation of high-affinity monoclonal antibodies and antigen-specific immune responses, even against the most complex or poorly immunogenic targets. Our technology can be applied in both therapeutic antibody development and next-generation vaccines, offering a versatile solution for tackling diseases with high unmet medical need. We are currently advancing a first-in-class antibody candidate for Alzheimer’s disease and are open to R&D collaborations, co-development, and licensing partnerships. BioClonal operates from its own labs and is actively engaging with pharma, biotech, and academic partners to expand the reach of its discovery engine.
Bioagile Therapeutics Private Limited
BioAgile Therapeutics Pvt Ltd is a full fledged Clinical Research Organization based in India providing an end to end clinical research and pharmacovigilance services to pharmaceutical, nutraceutical, biotech, herbs, cosmetics and medical device industries. We have the expertise in conducting trials and have strong affiliations with multiple investigators across diverse therapeutic domains, we excel in delivering excellence from phase I to phase IV, safety, efficacy and label claims assessment. Our services also encompasses pharmacovigilance services such as case processing, signal detection, aggregate reporting and regulatory compliance. With a proven track record of conducting trials and over 120 studies successfully completed, along with 30 national and international publications, we offer unparalleled expertise. | BioAgile Therapeutics Pvt. Ltd. is a full-fledged Clinical Research Organization (CRO) based in India, offering comprehensive, end-to-end clinical research services to the pharmaceutical, nutraceutical, biotech, herbal, cosmetics, and medical device industries. We are committed to delivering scientifically robust, ethically sound, and regulatory-compliant clinical solutions tailored to meet the diverse needs of our clients. Our core services encompass the entire spectrum of clinical development—ranging from Phase I to Phase IV clinical trials. In addition, we specialize in safety, efficacy, and label claims assessment studies, particularly relevant for the nutraceutical, herbal, medical device and cosmetic segments. Our capabilities are backed by a team of experienced professionals and a strong network of investigators across a wide range of therapeutic areas. BioAgile takes pride in its proven track record, having successfully completed over 130 clinical studies to date. Our scientific contributions are further reflected in 30+ publications featured in reputed national and international journals. These accomplishments underscore our dedication to quality, data integrity, and timely project execution. With a strong focus on innovation, collaboration, and regulatory excellence, BioAgile Therapeutics continues to be a trusted partner for clinical development programs in India and globally.
Bimini Pet Health
Bimini Pet Health is a contract manufacturer for dog and cat health supplements, treats and pet food based in Topeka, Kansas. The company manufactures products in different formats soft chews, powders, bars, liquids, Oils and baked goods. Bimini supports the products of over 50 third-party brands sold through platforms including Amazon and Chewy among others. The company is FDA and USDA registered and inspected and third-party audited according to 21 CFR Part 117 (human food) and the National Animal Supplements Council (NASC). In addition to being a contract manufacturer Bimini Pet Health recently launched it’s own premium veterinary brand “Bimini’s Best” featuring patent protected, trademarked and dog and cat efficacy-tested finished products and ingredients. Bimini welcomes inquiries from prospective clients who are seeking to manufacture high quality, innovative products. The company is also seeking partnerships to help ensure the success of it’s brand in the marketplace. | Bimini Pet Health is a pet health supplement and health treat contract manufacturer offering branded products and non-branded products available for private label. Our products come in the forms of soft chews, powders, baked treats, oils and liquids. Everything is produced in our, cGMP certified, USDA inspected and FDA registered manufacturing facilities with responsibly procured ingredients from US-based companies or provided by the client. Bimini is also an audited member of NASC. Bimini is committed to providing private label and custom manufactured pet supplements and health treats designed to support and maintain healthy and happy dogs, cats and horses. Our human grade, dosage form pet health supplements are compliant with 21CFR part 117 – cGMP Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food – and NASC cGMPs modeled after 21CFR 111 & 507 of the Federal Food, Drug and Cosmetic Act for Feed Supplements and Dosage Form Animal Health Products.
Bicoll GmbH
At Bicoll, we are committed to delivering breakthrough solutions in longevity and improving the lives of patients with neurodegenerative disorders such as epilepsy. Our innovative and efficient multi-disciplinary technology approach to the discovery of novel potent molecules for the pharmaceutical, nutraceutical, and agricultural industry is second to none. With a proven track record of success, Bicoll’s plant-based small molecule libraries have been documented in peer-reviewed publications and patents, demonstrating their efficacy in a wide range of applications. Looking to stay ahead of the curve in the highly competitive field of pharmaceuticals? Look no further than Bicoll, the expert in the field of plant small molecules backed up by strong medicinal chemistry. | At Bicoll we’re committed to pushing the boundaries of innovation and harnessing the power of existing compounds to address pressing healthcare challenges. Our latest endeavors in one of the projects have shown promising achievement for the landscape of anti-inflammatory treatments, CNS and taste-modulation. 1. We’re delving deep into the vast pool of existing compounds, uncovering hidden potentials and repurposing them for anti-inflammatory purposes. 2. Our dedicated team of researchers is employing cutting-edge techniques and methodologies to identify compounds with promising anti-inflammatory properties and novel pathways and mechanisms of action. 3. Collaboration is at the heart of our project. By partnering with esteemed institutions and industry experts, we’re fostering synergies and pooling our collective expertise to drive meaningful progress. Our ultimate goal extends beyond scientific advancement. A pioneer in the realm of drug discovery: it has consistently demonstrated unparalleled proficiency in the extraction and isolation of bioactive compounds from natural sources. I. Agriculture: Explore new horizons in agriculture through a strategic partnership with Bicoll. Pioneering novel structures and small molecules that can elevate your compound discovery program II. Adapalene re-purposing: Partnership/out-licensing for a re-purposing small molecule with clear mode of action and IP (patent published) III. Nutraceuticsls – Taste and flavor: Innovate and formulate new alternatives to the ingredients that are the target of sugar taxes. Creating novel sweeteners, flavor enhancers, or other compounds IV. Neuroscience: New chemical entity in the preclinical development: antiepileptic drugs for companion animals. 4NEURON – new spin-off – lead small molecule to change the lives of 50 Mio. Epilepsy patients. V. Compound library and medicinal chemistry: Uncover “dark matter” of medicinal plants. Fresh ideas for your screening | Bicoll is a trusted leader in biopharmaceutical drug discovery, specializing in high-tech natural product and medicinal chemistry to identify novel, small-molecule compounds that power the future of pharmaceuticals and beyond. Leveraging advanced techniques in natural compound identification and chemical synthesis, Bicoll accelerates the discovery of new drug candidates, providing companies with unique, high-potential compounds for preclinical research. Bicoll’s expertise extends to transformative solutions across pharmaceuticals, cosmetics, nutraceuticals, and agriculture, enabling partners to achieve breakthrough results with safe, effective, and innovative products. From Breakthrough Ideas to Life-Changing Solutions: See You at #BIO2025 in San Francisco! Not long ago, a family struggling with epilepsy shared their story with us—a story of endless challenges, countless medications, and the hope for a better future. Stories like theirs drive our mission at Bicoll every day: to turn complex scientific challenges into life-changing breakthroughs. The Problem: Discovering innovative treatments for conditions like epilepsy isn’t just about science—it’s about the people waiting for answers. At Bicoll, we believe in breaking barriers in drug discovery to deliver those answers faster, safer, and more effectively. The Solution: After years of relentless research, our team developed a game-changing small molecule. Tested in acute viable brain slices from multi-drug-resistant epilepsy patients, it has shown exceptional anti-seizure efficacy and an extraordinary reduction in side effects. This isn’t just progress; it’s a leap toward redefining epilepsy care and restoring hope. The Bigger Picture: Bicoll’s innovative approach to natural product and medicinal chemistry extends beyond epilepsy. From pharmaceuticals to cosmetics, nutraceuticals, and agriculture, we’re unlocking the potential of nature to create high-impact, safe, and transformative solutions.
ARTIALIS
COMPANY BACKGROUND Artialis is a European Contract Research and Development Organization (CRDO), founded in 2010 with a solid scientific foundation and offering customized R&D solutions. Whilst initiated in the field of musculoskeletal disorders, in 2024 ,we expanded our scope to include other age related disorders and healthy aging. The latter including research with food and food supplements, disease prevention and early diagnosis. ADDED VALUE We are not a generic CRDO as we are on a mission to promote healthy aging. We are an R&D hub providing all research activities to achieve this. Our services are tailored to our customers’ needs: not more not less. Artialis has strong and scientific team with experience in healthy aging doing the extra mile for our customers. We are pride ourselves to be flexible, proactive and operating in a partnership with our customers. Our proposals are very clear and detailed, in that way avoiding change orders and other surprises. RANGE OF PRODUCTS We offers customized solutions and support from the preclinical phase (in-vitro and in-vivo) to clinical and post marketing, as well as a wide range of clinical, imaging and biochemical markers to support the development of your products (medication, medical devices, nutraceuticals and food supplements). Our areas of expertise are: Mainly age related disorders, such as musculoskeletal, neurodegenerative and cardio metabolic diseases, but also pain, inflammation, immunity and gut. MAIN REFERENCES With more than 158 biotesting, preclinical and clinical projects successfully completed and 56% of our clients returning with more projects we are the leaders in our field.
Anivance AI
Anivance AI stands at the forefront of intelligent healthcare innovation, specializing in human organ model solutions. A decade of experience with respiratory models has driven us to achieve significant advancements in preclinical testing and earned us the prestigious 2023 Moderna Taiwan mRNA Innovation Award. This recognition is a testament to our unwavering commitment to improving healthcare and reflects our mission: Saving Lives: Now a Reality. Our comprehensive services, designed to accelerate the drug discovery and safety assessment processes, leverage human-simulated data to bridge the gap between laboratory findings and clinical applications. By precisely simulating human responses, we provide the pharmaceutical industry with powerful tools for thorough safety and efficacy evaluation. | Anivance AI is bridging Taiwan’s world-class semiconductor and manufacturing expertise with AI and life sciences, creating a new era of intelligent drug discovery. By integrating AI-powered organ-on-chip technology with automated high-throughput research, we provide pharmaceutical companies with a scalable, self-optimizing platform that accelerates preclinical testing and delivers breakthrough insights. Unlike traditional preclinical models, our platform is continuously learning and adapting, optimizing experiment design, mechanistic analysis (MOA), and real-time data interpretation. By embedding AI agents into automated research workflows, we help pharmaceutical companies make faster, smarter, and more data-driven decisions, significantly reducing preclinical failure rates and improving R&D efficiency. With 25 granted and pending patents, Anivance AI collaborates with leading global pharmaceutical companies and six clinical institutions, ensuring that our technology is aligned with real-world drug development needs. We have validated our high-throughput organ-on-chip platform in lung, liver, and oncology models, with expanding applications in autoimmune diseases and cardiovascular research. Our breakthroughs in inhalable nanoparticle delivery and respiratory disease modeling have earned global recognition, including a nomination for the LUSH Prize in Science. By leveraging Taiwan’s semiconductor supply chain and precision manufacturing ecosystem, we deliver a new level of automation, AI-driven analytics, and experimental scalability that was previously unattainable in biotech. Backed by two of Taiwan’s largest publicly traded companies and validated by over 50 collaborating physicians, Anivance AI is one of Taiwan’s fastest-growing biotech startups, now expanding into the global market. We are not just developing technology—we are reshaping the future of AI-powered drug discovery. With a foundation built on semiconductor precision, AI intelligence, and biotech innovation, Anivance AI provides pharmaceutical companies with the tools to make transformative breakthroughs, faster than ever before. | Anivance AI is a deep tech company developing Physical AI infrastructure for decision-grade human biology in early drug development and translational research. Rather than operating as a service provider or a single model technology, Anivance AI is designed as an integrated system. Physical organ models function as the sensing layer. Standardized execution and biological baselines form the control layer. Structured data intelligence provides the reasoning layer. Together, these components support closed loop experimentation and decision making. We integrate three tightly coupled layers into a single Physical AI platform. 1. Engineering grade physical organ systems Hard structured organ on chip and microphysiological systems designed for long term stability and reproducible operation under dynamic physiological conditions. The systems support continuous microfluidic circulation, vascular side dosing, dynamic exposure workflows including inhalation relevant conditions, and long duration experiments. 2. Standardized biological baselines and profiles Reusable organ and disease profiles that define execution and interpretation standards, reduce variability across batches and operators, and enable cross study comparability. 3. Human data foundry and decision loop Integrated imaging, functional readouts, and structured experimental metadata form a continuously accumulating human data infrastructure. This supports AI assisted analysis, iterative model refinement, and decision oriented reporting aligned with regulatory expectations. The platform has been deployed across lung and inhalation, liver, kidney, CNS and BBB, oncology, and rare disease applications, supporting more than 25 experimental programs across North America, Japan, South Korea, and Europe. | Anivance AI Corporation is a tech startup integrating miniaturized human organ systems on chips with Multi-Agent AI to accelerate drug discovery. Backed by 35 patents and thousands of data points across multiple organ and disease models, Anivance AI advances 20+ projects and expands across North America, Japan, South Korea, and Europe.
AmbioPharm, Inc.
AmbioPharm is a global leader in peptide manufacturing, specializing in the development and production of peptide-based Active Pharmaceutical Ingredients (APIs). Founded in 2005 and headquartered in North Augusta, South Carolina, USA, we are a patient-focused Contract Development and Manufacturing Organization (CDMO) with a reputation for technical excellence, innovation, and cost-effective solutions. Our state-of-the-art facilities in South Carolina, USA, and Shanghai, China, manufacture New Chemical Entities (NCEs) and peptide APIs under cGMP compliance, supporting pharmaceutical and biotech clients worldwide. AmbioPharm provides comprehensive peptide manufacturing solutions that support our clients from early-stage development through full-scale commercial production. Our expertise covers solid-phase, solution-phase, and hybrid synthesis, as well as organic conjugations to proteins, toxoids, antifungals, KLH (Keyhole Limpet Hemocyanin), and PEG (Polyethylene Glycol). We offer end-to-end peptide development services, including scale-up, validation, and process qualification leading up to New Drug Application (NDA) submissions with the U.S. Food and Drug Administration (FDA). With our advanced manufacturing facilities, robust quality systems, and cost-effective approach, AmbioPharm is the trusted partner for pharmaceutical and biotech companies seeking high-quality peptide APIs for both clinical and commercial applications. | AmbioPharm is a global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at clinical and commercial stages. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA as well as other global regulatory bodies with excellent outcomes. Our mission is to accelerate your peptides to patients.
ABIFINA
ABIFINA is a non-profit organization made up by private and public companies that produce medicines, vaccines, biological and chemical intermediates, natural products, medicines for animal health and products for agrobusiness.